We first used the OCI-AML3 xenotransplantation model, which carries both NPM1 and DNMT3A mutations and serves as an aggressive model of DNMT3A–NPM1-mutated AML, in which terminal disease develops within 3 weeks of transplantation49. Here, RUNX2 is linked to acute myeloid leukemia.